NCT06396247 Impact of Brief Daily Functional Resistance Training on Lower Extremity Physical Performance
| NCT ID | NCT06396247 |
| Status | Recruiting |
| Phase | Phase 2, Phase 3 |
| Sponsor | Milton S. Hershey Medical Center |
| Condition | Mobility Limitation |
| Study Type | INTERVENTIONAL |
| Enrollment | 360 participants |
| Start Date | 2025-04-09 |
| Primary Completion | 2028-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
In Phase 2, researchers evaluate early signs of effectiveness. You may be randomized to receive the active treatment or a comparator. Monitoring continues closely.
This trial targets 360 participants in total. It began in 2025-04-09 with a primary completion date of 2028-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
In this study, we will randomly assign 360 older adults to 12 months of 5 minutes per day of functional resistance training or to a delayed treatment control condition, and measure the impact of the training on measures of lower extremity performance and walking ability.
Eligibility Criteria
Inclusion Criteria: * Self-reported difficulty or inability to walk ¼ mile Exclusion Criteria: * Chest pain on the PAR-Q
Contact & Investigator
Maggie Nellissery, Ph.D.
STUDY CHAIR
National Institute on Aging (NIA)
Frequently Asked Questions
Who can join the NCT06396247 clinical trial?
This trial is open to participants of all sexes, aged 65 Years or older, studying Mobility Limitation. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT06396247 trial and what does that mean for participants?
Phase 2 trials evaluate whether the treatment shows signs of effectiveness while continuing to monitor safety. More participants are enrolled than in Phase 1 to help refine the treatment protocol.
Is NCT06396247 currently recruiting?
Yes, NCT06396247 is actively recruiting participants. Contact the research team at cns10@psu.edu for enrollment information.
Where is the NCT06396247 trial being conducted?
This trial is being conducted at Hershey, United States, Pittsburgh, United States.
Who is sponsoring the NCT06396247 clinical trial?
NCT06396247 is sponsored by Milton S. Hershey Medical Center. The principal investigator is Maggie Nellissery, Ph.D. at National Institute on Aging (NIA). The trial plans to enroll 360 participants.